SPP1 and myeloid sarcoma: Consequently, as comparison of OPN levels between people with MS and OND rendered no differences, this biomarker would seem to lack enough specificity for a differential diagnosis of MS when other neurological conditions are considered, and OPN should be combined with additional tests to gain specificity for MS diagnosis.